eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2008
vol. 12
 
Share:
Share:
more
 
 
abstract:

Hypoxia in uterine cervical cancer: impact on treatment

Janina Markowska
,
Radosław Mądry
,
Jacek Grabowski
,
Karolina Jaszczyńska-Nowinka,
,
Monika Szarszewska

Współczesna Onkologia (2008) vol. 12; 1 (11–15)
Online publish date: 2008/03/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Rapid proliferation of tumour results in production of pro-angiogenic factors due to tissue hypoxia. However, the new abnormal blood supply cannot provide correct oxygenation, so low oxygen tension remains, causing resistance to radio-/chemotherapy and increasing the risk of metastases. There are known substances, hypoxia markers, whose level significantly increases in oxygen deficiency. They are: HIF-1a (hypoxia inducible factor 1a), CA9 (carboanhydrase 9) and GLUT1 (glucose transporter 1). It is proved that among patients at the same stage of cervical cancer, women with high hypoxia markers’ expression have shorter disease-free survival and overall survival time. Many attempts have been made to use hypoxia in target therapy by introducing modified radio-/chemotherapy schemes, 2C3 antibodies, which block VEGF, YC-1 inactivating HIF-1a and bortezomib, a proteasome inhibitor responsible for blocking angiogenesis and apoptosis promotion. It is believed that routine examination of hypoxia markers may allow in future the planning of treatment adjusted individually to every patient.
keywords:

cervical cancer, hypoxia markers, hypoxia

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe